TME Pharma NV (XPAR:ALTME) EBITDA Margin %: 1,148.15% (As of Dec. 2025)


What is TME Pharma NV EBITDA Margin %?

TME Pharma NV XPAR:ALTME -3.45% EBITDA Margin % is 1,148.15% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 937 Biotechnology companies, TME Pharma NV ranks worse than 106723.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. TME Pharma NV's EBITDA for the six months ended in Dec. 2025 was €-0.31 Mil. TME Pharma NV's Revenue for the six months ended in Dec. 2025 was €-0.03 Mil. Therefore, TME Pharma NV's EBITDA margin for the quarter that ended in Dec. 2025 was 1,148.15%.

TME Pharma NV  (XPAR:ALTME) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

TME Pharma NV EBITDA Margin % Related Terms

TME Pharma NV EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV EBITDA Margin % Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -6,955.56 1,148.15

XPAR:ALTME vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, TME Pharma NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's EBITDA Margin % falls into.


TME Pharma NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

TME Pharma NV's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.188/0
= %

TME Pharma NV's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.31/-0.027
=1,148.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 1,148.15% mean?
TME Pharma NV (XPAR:ALTME) has a EBITDA Margin % of 1,148.15% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 937 companies in the Biotechnology industry.
Is TME Pharma NV's EBITDA Margin % too high?
TME Pharma NV's current EBITDA Margin % is 1,148.15%. Based on the distribution chart, TME Pharma NV ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 937 companies for EBITDA Margin %. This places TME Pharma NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current EBITDA Margin % is 1,148.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current EBITDA Margin % of 1,148.15%. The current EBITDA Margin % is 1,148.15%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current EBITDA Margin % is 1,148.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.